Demographic and clinical predictors of leptomeningeal collaterals in stroke patients

J Stroke Cerebrovasc Dis. 2014 Sep;23(8):2018-2022. doi: 10.1016/j.jstrokecerebrovasdis.2014.02.018. Epub 2014 Aug 1.

Abstract

Background: Leptomeningeal collaterals improve outcome after stroke, including reduction of hemorrhagic complications after thrombolytic or endovascular therapy, smaller infarct size, and reduction in symptoms at follow-up evaluation. The purpose of this study was to determine the demographic and clinical variables that are associated with a greater degree of cerebral collaterals.

Methods: Clinical data of patients presenting with M1 occlusions of the middle cerebral artery (MCA) and associated computed tomography angiography studies after admission from 3 separate institutions were retrospectively compiled (n = 82). Occluded hemispheres were evaluated against the intact hemisphere for degree of collateralization in the MCA territory. Regression analysis of variance was conducted between clinical variables and collateral score to determine which variables associate with greater collateral development.

Results: Smaller infarct size corresponded to greater collateral scores, whereas older age and statin use corresponded to lower collateral scores (P < .001).

Conclusions: Cerebral collateralization is influenced by age and statin use and influences infarct size.

Keywords: Predictors of collaterals in stroke; collaterals; computed tomography angiography; prediction; stroke.

MeSH terms

  • Aged
  • Aging / pathology*
  • Brain Infarction / physiopathology
  • Cerebral Angiography
  • Collateral Circulation*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Male
  • Middle Aged
  • Middle Cerebral Artery / diagnostic imaging*
  • Middle Cerebral Artery / pathology
  • Retrospective Studies
  • Risk Factors
  • Stroke / diagnostic imaging
  • Stroke / pathology
  • Stroke / physiopathology*
  • Tomography, X-Ray Computed

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors